Dr Dawson is chief of Adolescent Medicine Services, Carl R Darnall Army Medical Center Pediatric Clinic, Fort Hood, Texas.

Researchers at Children’s Healthcare of Atlanta and Georgia Tech are testing an AI tool to detect worsening teen mental health online. As concerns grow about the effects of social media on adolescent ...

US measles cases reached 1,842 as of May 7, 2026, marking the highest annual total in 35 years. Pediatric organizations emphasized on-time MMR vaccination to protect infants and vulnerable children.

An international consensus group has recommended renaming PCOS to polyendocrine metabolic ovarian syndrome (PMOS). The new terminology is intended to better reflect the endocrine and metabolic ...

Chronic pediatric skin disorders cause significant stigma, bullying, depression, and suicide risk—conditions often underrecognized and undertreated by physicians. Pediatric patients with chronic skin ...

The FDA is warning diabetes patients that information from CGMs, insulin pumps, and automated dosing systems could fail to be delivered if smartphone settings are not properly configured.

The latest scientific statement from the American Heart Association takes aim at offering clinicians with a summary of contemporary evidence related to the prevalence and increase in long-term risk ...

Explore essential menstrual product options and education for adolescents, addressing safety, comfort, and personal preferences in menstrual health. Patient preferences and skills will likely ...

Infant formula safety reaffirmed: Most samples had undetectable or very low contaminant levels, supporting the safety of the US formula supply. Contaminants detected at very low levels: When present, ...

AbbVie filed an sNDA for upadacitinib to treat severe alopecia areata in adults and adolescents based on phase 3 UP-AA trial results. AbbVie has submitted a supplemental new drug application (sNDA) to ...

The FDA approved lunsotogene parvec-cwha as the first gene therapy for genetic hearing loss caused by biallelic OTOF variants. The US Food and Drug Administration (FDA) has approved lunsotogene parvec ...

FDA expanded teplizumab use to children aged ≥1 year with stage 2 T1D, enabling earlier intervention. Availability of therapy may increase screening and identification of at-risk pediatric patients.